LUND, Sweden, Jan. 20, 2022 /PRNewswire/ -- Immunovia AB (publ)
announces that Philipp Mathieu has
been appointed acting CEO and President with immediate effect. The
search for a permanent CEO continues, as previously
communicated.
Philipp Mathieu has extensive
experience as an adviser on corporate strategy, M&A and capital
markets transactions to healthcare and life sciences companies,
both in Europe and in the US. He
has also held leadership positions in the financial sector and has
extensive proficiency as an investor. The Board has entrusted him
to rapidly advance the strategic priorities of the company, while
it rolls out its pioneering IMMray™ PanCan-d test in the US.
"The appointment of Philipp as acting CEO ensures that we
maintain our strategic momentum. I am pleased to welcome Philipp
whose experience both in Europe
and the US will be a valuable addition to the company. He possesses
the qualifications and experience which Immunovia needs at present,
and I look forward to working closely with him to realize the next
phase of development of Immunovia", says Carl Borrebaeck, Chairman
of the Board of Directors at Immunovia.
For more information, please contact:
Carl Borrebaeck
Chairman of the Board
+46 70 821 83 30
carl.borrebaeck@immun.lth.se
Tobias Bülow
Senior Director Investor Relations and Corporate Communications
+46 736 36 35 74
tobias.bulow@immunovia.com
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 08:30 CET
January 20, 2022.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer based on Immunovia's proprietary test platform
called IMMray™. Tests are based on antibody biomarker
microarray analysis using advanced machine-learning and
bioinformatics to single-out a set of relevant biomarkers that
indicate a certain disease. Thus, forming a unique "disease
biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
PanDIA-1.
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please
visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-appoints-philipp-mathieu-as-acting-ceo,c3489337
The following files are available for download:
https://mb.cision.com/Main/13121/3489337/1522757.pdf
|
Press release
(PDF)
|